GlassScriptPhysician profile
Michaela Manias
NPI 1154178150
$2,886.06
in general payments reported to CMS, 2019-2025
44 companies · $2,374 in 2025
The $2,374 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $512 · 2025: $2,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,671 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,671.06 |
| Education | $215.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $423.81 | 2024-2025 | Datroway, Imfinzi, Tagrisso |
| Regeneron Healthcare Solutions, INC. | $196.70 | 2025 | Libtayo |
| Merck Sharp & Dohme LLC | $167.36 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Stryker Corporation | $162.64 | 2025 | Optablate |
| Janssen Biotech, INC. | $145.93 | 2025 | Carvykti, Rybrevant, Darzalex |
| Sobi, INC | $138.26 | 2024-2025 | |
| Daiichi Sankyo INC. | $119.48 | 2024-2025 | Enhertu, Datroway |
| Eisai INC. | $111.08 | 2025 | |
| Genentech, INC. | $102.70 | 2024 | Tecentriq |
| Seagen INC. | $99.99 | 2025 | |
| Genzyme Corporation | $86.31 | 2025 | |
| Pfizer INC. | $72.46 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.39 | 2024-2025 | Iclusig, Fruzaqla |
| Beone Medicines USA, INC. | $66.53 | 2025 | Tevimbra, Brukinsa |
| Genentech USA, INC. | $55.98 | 2024-2025 | Columvi, Polivy, Lunsumio |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $53.70 | 2025 | Ojjaara, Jemperli, Zejula |
| Astellas Pharma US INC | $48.60 | 2025 | Vyloy, Xospata |
| Pharmaessentia USA Corporation | $44.65 | 2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $39.76 | 2025 | |
| Exelixis INC. | $39.60 | 2024-2025 | Cabometyx |
| Legend Biotech USA INC. | $37.89 | 2025 | Carvykti |
| Blueprint Medicines Corporation | $36.45 | 2025 | Ayvakit |
| Acrotech Biopharma INC. | $35.50 | 2024-2025 | Beleodaq |
| Abbvie INC. | $33.09 | 2025 | |
| Recordati_rare_diseases_inc. | $32.95 | 2025 | Enjaymo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.62 | 2024 | |
| Array Biopharma INC | $32.32 | 2025 | Braftovi, Tukysa, Mektovi |
| Csl Behring | $29.47 | 2024 | Hizentra |
| Kite Pharma, INC. | $29.37 | 2025 | Yescarta |
| Dendreon Pharmaceuticals LLC | $28.55 | 2025 | Provenge |
| Tersera Therapeutics LLC | $28.37 | 2024 | Zoladex |
| Gilead Sciences, INC. | $28.12 | 2025 | Trodelvy |
| Servier Pharmaceuticals LLC | $25.00 | 2025 | |
| Rigel Pharmaceuticals, INC. | $24.98 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Kyowa Kirin, INC. | $24.35 | 2025 | |
| Puma Biotechnology, INC. | $24.01 | 2025 | |
| Stemline Therapeutics INC. | $22.01 | 2025 | Orserdu |
| Azurity Pharmaceuticals, INC. | $21.48 | 2025 | Vivimusta, Danziten |
| Genmab U.S., INC. | $20.12 | 2024 | Epkinly |
| Lilly USA, LLC | $19.26 | 2025 | Verzenio, Jaypirca |
| Alnylam Pharmaceuticals INC. | $18.42 | 2025 | Givlaari |
| Novartis Pharmaceuticals Corporation | $18.38 | 2025 | |
| Agios Pharmaceuticals, INC. | $17.72 | 2024 | |
| Incyte Corporation | $17.70 | 2025 | Monjuvi, Zynyz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Manias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.